Abstract
The hypoxic cell-radiosensitizing drug misonidazole (1-(2-nitroimidazol-1-yl)-3-methoxypropan -2 -ol, Ro 07-0582, MIS) was administered at a dose of 150 mg/kg i.v. to 6 dogs bearing spontaneous tumours, and the resulting tumour concentrations were measured to HPLC analysis. In 4 dogs it was possible to obtain serial biopsy specimens up to 5 h. With the exception of a brain tumour, the tumour concentrations ranged between 47% and 95% of the plasma concentration, most of the values falling within the range 50--70%. Concentrations in the brain tumour were markedly lower. Barbiturate anaesthesia was necessary for the removal of the serial biopsy specimens, and the effects of sodium pentobarbitone anaesthesia on the pharmacokinetics of MIS were investigated in 2 dogs. After barbiturate anaesthesia peak plasma concontrations were raised and the availability of MIS was increased, although the biological half-life remained unaltered. The metabolism of MIS to the O-demethylated metabolite, Ro 05-9963, was delayed initially. The concentrations of MIS AND Ro 05-9963 in cerebrospinal fluid were also recorded in these dogs; MIS concentrations were found to approach those of the plasma, whereas the metabolite concentrations were considerably lower (0--58% of the plasma concentration).
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Asquith J. C., Watts M. E., Patel K., Smithen C. E., Adams G. E. Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiat Res. 1974 Oct;60(1):108–118. [PubMed] [Google Scholar]
- Brown J. M., Yu N. Y., Workman P. Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours. Br J Cancer. 1979 Mar;39(3):310–320. doi: 10.1038/bjc.1979.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McNally N. J., Denekamp J., Sheldon P., Flockhart I. R., Stewart F. A. Radiosensitization by misonidazole (Ro 07-0582). The importance of timing and tumor concentration of sensitizer. Radiat Res. 1978 Mar;73(3):568–580. [PubMed] [Google Scholar]
- Urtasun R. C., Band P., Chapman J. D., Rabin H. R., Wilson A. F., Fryer C. G. Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative. Radiology. 1977 Mar;122(3):801–804. doi: 10.1148/122.3.801. [DOI] [PubMed] [Google Scholar]
- Wiltshire C. R., Workman P., Watson J. V., Bleehen N. M. Clinical studies with misonidazole. Br J Cancer Suppl. 1978 Jun;3:286–289. [PMC free article] [PubMed] [Google Scholar]
- Workman P., Little C. J., Marten T. R., Dale A. D., Ruane R. J., Flockhart I. R., Bleehen N. M. Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr. 1978 May 1;145(3):507–512. doi: 10.1016/s0378-4347(00)81386-9. [DOI] [PubMed] [Google Scholar]
- Workman P., Wiltshire C. R., Plowman P. N., Bleehen N. M. Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring. Br J Cancer. 1978 Dec;38(6):709–718. doi: 10.1038/bjc.1978.277. [DOI] [PMC free article] [PubMed] [Google Scholar]